Wahed Invest LLC Acquires 351 Shares of Hologic, Inc. (NASDAQ:HOLX)

Wahed Invest LLC boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.3% during the fourth quarter, HoldingsChannel reports. The fund owned 5,902 shares of the medical equipment provider’s stock after purchasing an additional 351 shares during the quarter. Wahed Invest LLC’s holdings in Hologic were worth $425,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after purchasing an additional 144,838 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after buying an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after acquiring an additional 129,035 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock worth $293,434,000 after acquiring an additional 572,187 shares during the period. Finally, Boston Partners boosted its holdings in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Down 5.4 %

NASDAQ:HOLX opened at $54.16 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a one year low of $52.12 and a one year high of $84.67. The company has a market cap of $12.15 billion, a PE ratio of 17.09, a PEG ratio of 2.14 and a beta of 0.54. The firm has a 50-day moving average of $60.28 and a 200-day moving average of $69.26.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.03 EPS. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

HOLX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Friday. Royal Bank of Canada cut their price target on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Friday. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Morgan Stanley decreased their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $81.15.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.